Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The integrity of the Circle of Willis predicted hemodynamic changes after bypass surgery in Moyamoya disease: a prospective cohort study by 4D flow MRI.

AJNR. American journal of neuroradiology·2026
Same author

Territorial heterogeneity of atherosclerosis and vascular calcification.

Nature cardiovascular research·2026
Same author

A modular, high-bandwidth, bidirectional implantable device for neural interrogation.

Journal of neural engineering·2026
Same author

Radiomic Carotid Plaque Features Integrated into Machine Learning Models for Cardiovascular Risk Prediction.

Ultrasound in medicine & biology·2026
Same author

Estradiol-to-oocyte ratio as a prognostic biomarker of assisted reproductive outcomes in women with polycystic ovary syndrome: The impact of LH activity.

Women's health (London, England)·2026
Same author

Risk prediction and prevention in patients with advanced subclinical atherosclerosis.

BMC cardiovascular disorders·2026

Related Experiment Video

Updated: Jun 8, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K

Cardiovascular Disease Risk Stratification Using Hybrid Deep Learning Paradigm: First of Its Kind on Canadian Trial

Mrinalini Bhagawati1, Sudip Paul1, Laura Mantella2

  • 1Department of Biomedical Engineering, North-Eastern Hill University, Shillong 793022, India.

Diagnostics (Basel, Switzerland)
|September 14, 2024
PubMed
Summary
This summary is machine-generated.

Hybrid deep learning (HDL) models significantly improve cardiovascular disease (CVD) risk prediction from carotid plaques compared to traditional machine learning. AtheroEdge™ 3.0HDL demonstrates superior performance and clinical adaptability for enhanced CVD risk stratification.

Keywords:
and stabilitycardiovascular disease riskhybrid deep learningmachine learning feature extractionperformance evaluationreliabilityscientific validation

More Related Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.7K

Related Experiment Videos

Last Updated: Jun 8, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.7K

Area of Science:

  • Artificial Intelligence in Medical Imaging
  • Cardiovascular Disease Risk Prediction
  • Deep Learning for Healthcare

Background:

  • Cardiovascular disease (CVD) risk assessment traditionally relies on carotid plaque evaluation.
  • AtheroEdge™ 3.0HDL was developed to leverage carotid plaque features for improved CVD risk prediction.
  • The study hypothesizes that hybrid deep learning (HDL) surpasses other deep learning and machine learning (ML) approaches.

Purpose of the Study:

  • To evaluate the efficacy of AtheroEdge™ 3.0HDL in predicting cardiovascular disease (CVD) risk.
  • To compare the performance of hybrid deep learning (HDL) models against traditional machine learning (ML) and other deep learning paradigms.
  • To validate the reliability and clinical adaptability of the AtheroEdge™ 3.0HDL system.

Main Methods:

  • A study cohort of 500 individuals with carotid B-mode ultrasonography and coronary angiography data was analyzed.
  • Machine learning (ML) feature selection utilized principal component analysis (PCA), chi-square test (CST), and random forest regression (RFR).
  • Six novel hybrid deep learning (HDL) models were developed and validated against unidirectional/bidirectional deep learning and ML models using seen and unseen datasets.

Main Results:

  • The hybrid deep learning (HDL) system demonstrated a 30.20% performance improvement over the machine learning (ML) system on seen datasets (0.954 vs. 0.702).
  • ML feature extraction analysis revealed 70% commonality across PCA, CST, and RFR methods.
  • AtheroEdge™ 3.0HDL exhibited excellent generalization, with less than 1% difference between seen and unseen data (p-value < 0.001), meeting regulatory standards.

Conclusions:

  • The hypothesis was scientifically validated, confirming AtheroEdge™ 3.0HDL's superior performance in CVD risk prediction.
  • The AtheroEdge™ 3.0HDL model demonstrated reliability and stability through rigorous testing.
  • The system is clinically adaptable, offering potential for improved cardiovascular disease risk stratification.